In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Device/Diagnostics Quarterly Deal Statistics, Q2 2012

A look at financing, M&A, and alliance activity April–June 2012

Executive Summary

Medical device company financing brought in $977 million, a decrease over Q1’s $1.1 billion. Device acquisition activity was up to $4.6 billion, yet only one deal surpassed the billion-dollar mark. With late-stage financing again leading, diagnostics funding together brought in $336 million, an 11% increase over Q1. For the first time since Q1 2011, the diagnostics M&A dollar total moved up instead of down, with $7 billion in acquisitions and five of the seven transactions topping $100 million.

You may also be interested in...

The Renal Denervation Buzz: Separating Fact From Myth; Covidien Buys Maya Medical

Renal denervation was clearly the belle of this year’s EuroPCR, with more than a dozen sessions on the topic. In addition, just preceding the meeting, Covidien announced its acquisition of RDN start-up Maya Medical.

Hologic Grabs Gen-Probe

Women’s health-focused Hologic is buying molecular diagnostics provider Gen-Probe for $3.7 billion in cash. Adding Gen-Probe’s automated instrument platforms gives Hologic critical mass in the molecular diagnostics market while allowing it to maintain its core focus on women’s health. Hologic’s international direct sales force and dealer network can further drive adoption of US-oriented Gen-Probe’s tests in both developed and emerging markets. It also gives Gen-Probe a much greater capability for selling to physicians as well as labs, filling a second significant gap in Gen-Probe’s marketing.

Hologic Increases Bets In Lab Space With $3.7 Bil. Gen-Probe Purchase

Lab diagnostic products will actually account for a larger portion of Hologic’s business post-acquisition than the firm’s core mammography, ultrasound and magnetic resonance imaging offerings.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts